Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 4/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.49 |
| ▸ | CCR3 | P51677 | 2/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.46 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.46 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.46 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070394 | 0.89 | HPGDS (0.67) | HPGDSCCR3PRKAA2PRKAB2PRKAG1 | |
| SCHEMBL2073816 | 0.88 | HPGDS (0.66) | HPGDSCCR3PRKAA2PRKAB2PRKAG1 | |
| SCHEMBL2072774 | 0.88 | HPGDS (0.66) | HPGDSCCR3PRKAA2PRKAB2PRKAG1 | |
| SCHEMBL2071292 | 0.87 | HPGDS (0.65) | HPGDSCCR3PRKAA2PRKAB2PRKAG1 | |
| SCHEMBL2073206 | 0.87 | HPGDS (0.65) | HPGDSCCR3PRKAA2PRKAB2PRKAG1 | |
| SCHEMBL2072108 | 0.87 | HPGDS (0.63) | HPGDSCCR3PRKAA2BCHEACHE | |
| SCHEMBL2070306 | 0.87 | HPGDS (0.60) | HPGDSSLC2A1CCR3KCNH2 | |
| SCHEMBL2073522 | 0.85 | HPGDS (0.68) | HPGDSCCR3PRKAA2PRKAB2PRKAG1 | |
| SCHEMBL2072331 | 0.85 | HPGDS (0.63) | HPGDSCCR3PRKAA2PRKAB2PRKAG1 | |
| SCHEMBL2070158 | 0.84 | HPGDS (0.71) | HPGDSCCR3PRKAA2KCNH2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | HPGDS 984/4885SLC2A1 669/4885CCR3 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.